输血依赖型β地中海贫血老年患者房颤患病率与管理:FATHAL研究
这项多中心回顾性研究纳入9个中心1389例输血依赖型β地中海贫血患者,评估房颤患病率及管理现状。房颤患病率为11.9%,66岁以上人群达31%。导管消融 performed in 26.6%无并发症,74.4%症状改善。卒中患病率5.5%,CHA2DS2-VASc评分存在局限性,需制定特异性指南。
要点
- 输血依赖型β地中海贫血患者房颤患病率11.9%,66岁以上达31%。
- 首次房颤平均年龄40岁,多数患者存在左房扩大。
- 导管消融26.6%无并发症,74.4%症状改善。
核心结论
- 本研究为首个评估输血依赖型β地中海贫血房颤患病率的研究,患病率高于一般人群。
- CHA2DS2-VASc评分在该人群存在局限性,需制定特异性指南以优化诊疗。
研究设计与样本
- 多中心回顾性研究,9个中心参与,观察1389例输血依赖型β地中海贫血患者。
- 纳入188例有房颤病史的患者,61%为男性,73%已切脾。
主要发现
- 房颤患病率为11.9%,66岁以上人群达31%。
- 首次房颤发作平均年龄40岁;最常见已知危险因素为糖尿病、心力衰竭和吸烟。
- 近半数患者房颤前有心脏铁过载史,三分之一在首次事件时存在心脏铁过载。
- 多数患者存在左房扩大;卒中患病率5.5%,包括短暂性脑缺血发作时升至7.9%,其中88%患者已切脾。
- 超过半数患者CHA2DS2-VASc评分低,抗凝治疗期间发生9起事件。
关键数值与推荐
- 房颤患病率11.9%,66岁以上人群31%。
- 导管消融 performed in 26.6%无并发症,74.4%报告症状改善。
- 卒中患病率5.5%,包括短暂性脑缺血发作时7.9%。
- 超过半数患者CHA2DS2-VASc评分低。
临床怎么用
- 对输血依赖型β地中海贫血患者应关注房颤筛查,尤其是高龄、切脾及有心脏铁过载史者。
- 导管消融可作为改善症状的治疗选择,但需注意CHA2DS2-VASc评分可能低估卒中风险。
局限性
- 回顾性研究设计。
- CHA2DS2-VASc评分在该人群的适用性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Atrial fibrillation (AF) represents an emerging challenge in thalassemia due to the increasing life expectancy. However, data are limited, and management relies on guidelines for the general population. We conducted a multicenter retrospective study to assess the prevalence of AF in transfusion-dependent beta-thalassemia (β-TDT). Nine centers, observing 1389 patients, participated in the study; 188 patients with a history of AF were included, 61% were male, and 73% splenectomized. The mean age at the first AF episode was 40 years. The prevalence of AF was 11.9%, reaching 31% in individuals aged >66 years. Among the known risk factors, the most common were diabetes, heart failure, and smoking. Regarding disease-specific factors, a history of cardiac iron overload was present in almost half of the patients before AF and in one-third at the time of the first event. Most patients exhibited left atrial dilatation, which can result from anemia. Transcatheter ablation was performed in 26.6% without any complications, and 74.4% reported improvement in symptoms, the primary aim of the procedure. The stroke prevalence was 5.5%, rising to 7.9% when including transient ischemic attacks, with 88% of patients being splenectomized. The CHA2DS2-VASc score was low in more than half of the patients, and 9 events occurred during anticoagulant therapy. This study is, to our knowledge, the first to evaluate AF prevalence in β-TDT, which is higher than in the general population. The CHA2DS2-VASc score has some limitations, and specific guidelines are necessary to provide optimal care for these patients.
引用
- Di Stefano V, Gianesin B, Orecchia V, et al. Atrial fibrillation prevalence and its management in aging, transfusion-dependent patients with thalassemia: the FATHAL study. Blood Adv. 2026. PMID: 41569798. doi:10.1182/bloodadvances.2025017577
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。